Related Experiment Videos
Anti-thymocyte globulin induced thrombocytopenia
J Lazarchick1, R Russell, B Horn
1Department of Pathology/Laboratory Medicine, Medical University of South Carolina, Charleston 29425.
Annals of Clinical and Laboratory Science
|November 1, 1990
Summary
Anti-thymocyte globulin (ATG) shows strong reactivity with platelets, independent of HLA type. Horse ATG binds specifically to platelet glycoproteins V and IIa, saturating binding sites at low concentrations.
Area of Science:
- Immunology
- Hematology
- Transfusion Medicine
Background:
- Anti-thymocyte globulin (ATG) is a polyclonal antibody preparation used to treat immune-mediated conditions.
- The interaction of ATG with platelets is not fully understood, despite potential clinical implications.
Purpose of the Study:
- To investigate the reactivity of ATG with human platelets.
- To identify the specific platelet components targeted by ATG.
Main Methods:
- Flow cytometric analysis was used to measure ATG-platelet reactivity.
- Immunoblot studies were performed on platelet membrane proteins.
Main Results:
- ATG demonstrated strong reactivity with platelets, independent of human leukocyte antigen (HLA) phenotype.
- Platelet binding sites were saturated with horse ATG at 0.25 mg/ml, indicating dose-dependency.
- Reactivity could not be blocked by human anti-PLA1 antibody or heat-aggregated human IgG.
- Immunoblotting suggested ATG antibodies target platelet glycoproteins V and IIa.
Conclusions:
- Horse ATG exhibits specific binding to platelet glycoproteins V and IIa.
- This interaction is dose-dependent and occurs independently of HLA type.